RxDoctor Payments DataLook up a doctor →

Alan Kricsfeld, MD

Internal Medicine · Council Bluffs, IANPI 1467406017

Payments from drug & device makers

$48,833in general payments, 2019–2025

Across 767 payments — averaging $63.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$25K
  • AstraZeneca$3K
  • Bayer$2K
  • AbbVie$2K
  • Amgen$2K
  • Medtronic$2K
  • plus $13K from 45 others

What the payments were for

  • Consulting fees$1,5033%
  • Speaking & faculty fees$22,22546%
  • Travel & lodging$1,0972%
  • Food & beverage$23,85049%
  • Education$1580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,833 in reported general payments places this provider in the 95th percentile of 583 internal medicine providers in Iowa.

See all internal medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$356,745
Medicare patients
434
Services billed
10,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide346$397,106
EliquisApixaban286$198,911
XareltoRivaroxaban161$133,026
JardianceEmpagliflozin82$73,899
OzempicSemaglutide64$61,077
TrulicityDulaglutide53$55,704
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$44,625
JanuviaSitagliptin Phosphate43$40,850
FarxigaDapagliflozin Propanediol41$38,676
Repatha SureclickEvolocumab36$30,081
TradjentaLinagliptin28$26,863
InvokanaCanagliflozin43$26,057
MyrbetriqMirabegron59$24,233
GemtesaVibegron42$21,517
KerendiaFinerenone20$15,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$838$452,810399 claims
PfizerEliquis$616$198,911286 claims
Johnson & JohnsonXarelto, Invokana$24,878$159,083204 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Jentadueto Xr, Trijardy Xr$474$140,965160 claims
Novo NordiskOzempic$1,146$61,07764 claims
MerckJanuvia, Janumet$229$51,78758 claims
GSKTrelegy Ellipta$677$44,62549 claims
AstraZenecaFarxiga, Symbicort$3,233$43,27054 claims
Astellas Pharma US IncMyrbetriq$296$24,23359 claims
Sumitomo Pharma America, Inc.Gemtesa$346$21,51742 claims
BayerKerendia$2,371$15,98320 claims
AbbVieSynthroid$1,862$5,03469 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 internal medicine providers in Iowa.

Other internal medicine in Council Bluffs

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →